{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:27:08Z","timestamp":1786120028166,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1097\/ftd.0b013e31821c2772","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T02:51:19Z","timestamp":1304477479000},"page":"303-308","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without HCV Coinfection, Receiving Boosted or Unboosted Regimens"],"prefix":"10.1097","volume":"33","author":[{"given":"Mario","family":"Regazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Brandolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Tinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Barassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Maserati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sighinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella D'Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Vico","family":"Melzi D'Eril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-200363080-00002","article-title":"Therapeutic drug monitoring. An aid to optimising response to antiretroviral drugs?","volume":"63","author":"Aarnoutse","year":"2003","journal-title":"Drugs"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2125.2005.02413.x","article-title":"Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.","volume":"60","author":"Ray","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R3-6-20210129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jac\/dkm298","article-title":"Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.","volume":"60","author":"Cleijsen","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/aid.2007.0276","article-title":"Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.","volume":"24","author":"Rodriguez-Novoa","year":"2008","journal-title":"AIDS Res Human Retrov"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association guidelines on the treatment of HIV-1-infected adults with antiretroviral therapy 2008.","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med"},{"issue":"suppl 2","key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/381453","article-title":"Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.","volume":"38","author":"Bonacini","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/381447","article-title":"Liver toxicity in epidemiological cohorts.","volume":"38","author":"Becker","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5009\/gnl.2007.1.2.145","article-title":"Shin, Sang Hoon Park, Sun-Young Jun, et al. Simple tests to predict hepatic fibrosis in non-alcoholic chronic liver diseases.","volume":"1","year":"2007","journal-title":"Gut Liver"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/clinchem\/45.9.1465","article-title":"Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study.","volume":"45","author":"Moyer","year":"1999","journal-title":"Clin Chem"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/dkp408","article-title":"Factors influencing lopinavir and atazanavir plasma concentration.","volume":"65","author":"Stohr","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.pharmtox.40.1.649","article-title":"Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.","volume":"40","author":"Flexner","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R16-6-20210129","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/FTD.0b013e31815704c1","article-title":"Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.","volume":"29","author":"Molto","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/FTD.0b013e3181897bff","article-title":"Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.","volume":"30","author":"Solas","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dki235","article-title":"Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.","volume":"56","author":"Winston","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R20-6-20210129","first-page":"120","article-title":"Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease.","volume":"21","author":"George","year":"1995","journal-title":"Hepatology"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome p450-mediated metabolism.","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkn045","article-title":"Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.","volume":"61","author":"Pineda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.","volume":"195","author":"Barreiro","year":"2007","journal-title":"J Infect Dis"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0091270005284853","article-title":"Pharmacokinetics of lopinavir\/ritonavir in HIV\/hepatitis C virus-coinfected subjects with hepatic impairment.","volume":"46","author":"Peng","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FTD.0b013e318177209e","article-title":"Lopinavir\/ritonavir pharmacokinetics in HIV\/HCV-coinfected patients with or without cirrhosis.","volume":"30","author":"Micheli","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus infected patients.","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-6-20210129","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-007-0344-y","article-title":"Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir boosted atazanavir in HIV-1-infected adults.","volume":"63","author":"Von Hentig","year":"2007","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31821c2772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:35:40Z","timestamp":1786044940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201106000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31821c2772","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}